Q&A

About Cellectis shares

1. On which stock exchange are the Cellectis shares listed ?

Cellectis shares are listed on the Alternext market of NYSE-Euronext Paris

under the ticker ALCLS and with the ISIN Code FR0010425595.

2. When was the company's first day of trading ?

Share trading started on February 7, 2007

3. How many outstanding shares does Cellectis have ?

As of January 1, 2010, 11,584,333 shares were outstanding. This number can be broken down as follows:

5,076,682 shares which made up the company's share capital prior to its IPO,
2,377,526 new shares (including those resulting from the exercise of the green shoe) issued in its IPO,
1,738,678 new shares issued in February 2007 via reimbursement of equity notes issued by the company in 2005,
18,730 issued as a result of the exercise of founders' warrants ("BSPCE"),
- 368,301 new shares issued in a share capital increase reserved to Regeron
- Pharmaceuticals, Inc, in October 2008,
- 90,416 new shares issued in a share capital increase reserved to Monsanto
- Company in October 2009, and
- 1,914,000 new shares issued in a private placement in October 2009.

4. How can I buy Cellectis shares ?

Cellectis shares can be acquired through any banker or stockbroker.

5. Does Cellectis pay a dividend to its shareholders ?

The Company is still loss-making and this will continue to be the case in the mid term. As such, no dividend payments are scheduled in the short term.

6. Does the company intend to proceed with a follow-on offering ?

Cellectis is not planning a follow-on offering in the coming months but has not ruled out this possibility as a way of financing its development in the future.

Top

About Cellectis' shareholders

1. Who are Cellectis' main investors ?

CELLECTIS' main shareholders are a group of venture capital investors who hold around 48% of the company's shares. The Institut Pasteur holds 5%, Regeneron Pharmaceuticals Inc. (3%) and the balance is held by the public (27%) and a number of individuals linked to the company, including its managers and staff (17%)

2. Are the Companys's main shareholders subject to a lock-up clause?

Yes, from the date of the IPO, a 9-month lock-up period applies to the lead investors, the Institut Pasteur, the company's Scientific Advisory Board, certain employees and other persons linked to the company, whereas the period is 12 months for the company's managers.

3. Where did the IPO investors come from?

The demand for shares can be broken down geographically as follows: 79% from France, 8.5% from the UK, 7% from Scandinavia and 5% from Switzerland and Germany

Top

About Cellectis' corporate governance

1. What is the Company's legal structure?

The Company is a French "Société Anonyme" (SA) with a Board of Directors.

Cellectis complies with the internal control legislation and its policy abides by principles of good corporate governance.
As CEO, André Choulika leads the company's management activities. He overseas the commercial policy and the R&D strategy and liaises between the various corporate departments.
He is assisted in this task by an informal Executive Board, which generates proposals for optimizing both the company's day-to-day affairs and its longer term strategy.

The company has adopted a range of internal audit and quality control procedures (particularly in the accounting and financial areas) with a view to hitting its strategic targets.

COMPANY MANAGEMENT